RxSight makes and sells the Light Adjustable Lens (LAL) system — the only intraocular lens (IOL) that can be adjusted after cataract surgery. In standard cataract surgery, a surgeon removes the patient's clouded natural lens and replaces it with an artificial IOL. Conventional IOLs are fixed at the time of surgery, requiring surgeons to predict the correct lens power in advance. RxSight's LAL works differently: after implantation, the doctor uses RxSight's Light Delivery Device (LDD) to expose the lens to UV light, which physically reshapes it to correct the measured refractive error. This process can be repeated up to three times before the lens is permanently locked. RxSight sells primarily to U.S. ophthalmology practices and ambulatory surgery centers through a direct sales force. RxSight operates a razor-and-blade model: the LDD capital device (the "razor") must be owned by a practice to use the system, while each procedure requires a new LAL consumable (the "blade"). As the installed LDD base grows, recurring LAL revenue grows with it. LAL revenue carries substantially higher margins than LDD revenue, so gross margins expand as LAL becomes a larger share of the mix. The key growth drivers are expanding the LDD installed base, increasing LAL utilization per device as practices gain experience, and converting high-volume cataract surgeons to the platform. RxSight also has regulatory approvals in several international markets, though international revenue remains minimal today.